Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization

Carvalho, A L, Miquel-Clopés, A, Wegmann, U, Jones, E, Stentz, R, Telatin, A, Walker, N J, Butcher, W A, Brown, P J, Holmes, S, Dennis, M J, Williamson, E D, Funnell, S G P, Stock, M and Carding, S R (2019) Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization. Clinical and Experimental Immunology, 196 (3). pp. 287-304. ISSN 0009-9104

[img]
Preview
PDF (Published_Version) - Published Version
Available under License Creative Commons Attribution.

Download (830kB) | Preview

Abstract

Plague caused by the Gram-negative bacterium, Yersinia pestis, is still endemic in parts of the world today. Protection against pneumonic plague is essential to prevent the development and spread of epidemics. Despite this, there are currently no licensed plague vaccines in the western world. Here we describe the means of delivering biologically active plague vaccine antigens directly to mucosal sites of plague infection using highly stable microvesicles (outer membrane vesicles; OMVs) that are naturally produced by the abundant and harmless human commensal gut bacterium Bacteroides thetaiotaomicron (Bt). Bt was engineered to express major plague protective antigens in its OMVs, specifically Fraction 1 (F1) in the outer membrane and LcrV (V antigen) in the lumen, for targeted delivery to the gastrointestinal (GI) and respiratory tracts in a non-human primate (NHP) host. Our key findings were that Bt OMVs stably expresses F1 and V plague antigens, particularly the V antigen, in the correct, immunogenic form. When delivered intranasally V-OMVs elicited substantive and specific immune and antibody responses, both in the serum [immunoglobulin (Ig)G] and in the upper and lower respiratory tract (IgA); this included the generation of serum antibodies able to kill plague bacteria. Our results also showed that Bt OMV-based vaccines had many desirable characteristics, including: biosafety and an absence of any adverse effects, pathology or gross alteration of resident microbial communities (microbiotas); high stability and thermo-tolerance; needle-free delivery; intrinsic adjuvanticity; the ability to stimulate both humoral and cell-mediated immune responses; and targeting of primary sites of plague infection.

Item Type: Article
Additional Information: © 2019 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Faculty of Science > School of Chemistry
Faculty of Medicine and Health Sciences > School of Health Sciences
Faculty of Science > School of Biological Sciences
Depositing User: LivePure Connector
Date Deposited: 24 Apr 2019 12:30
Last Modified: 14 Oct 2020 23:52
URI: https://ueaeprints.uea.ac.uk/id/eprint/70676
DOI: 10.1111/cei.13301

Actions (login required)

View Item View Item